iRadimed Corp. (IRMD) Sees Large Volume Increase
iRadimed Corp. (NASDAQ:IRMD) shares saw strong trading volume on Wednesday . 109,146 shares traded hands during trading, an increase of 43% from the previous session’s volume of 76,470 shares.The stock last traded at $19.00 and had previously closed at $18.90.
A number of equities research analysts have weighed in on the company. Zacks Investment Research downgraded iRadimed Corp. from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 5th. Roth Capital reaffirmed a “buy” rating on shares of iRadimed Corp. in a report on Tuesday, May 3rd.
The firm has a market cap of $199.25 million and a price-to-earnings ratio of 26.82. The company has a 50-day moving average of $18.62 and a 200 day moving average of $18.34.
iRadimed Corp. (NASDAQ:IRMD) last issued its quarterly earnings results on Friday, July 29th. The company reported $0.24 EPS for the quarter, topping analysts’ consensus estimates of $0.21 by $0.03. The business had revenue of $9.90 million for the quarter, compared to analyst estimates of $9.60 million. During the same quarter last year, the firm posted $0.16 EPS. iRadimed Corp.’s revenue for the quarter was up 30.3% on a year-over-year basis. On average, analysts anticipate that iRadimed Corp. will post $0.92 earnings per share for the current fiscal year.
In related news, Director Monty K. Allen sold 2,100 shares of the business’s stock in a transaction on Monday, June 13th. The shares were sold at an average price of $20.44, for a total value of $42,924.00. Following the transaction, the director now owns 4,375 shares in the company, valued at $89,425. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, VP Steven M. Nardi sold 2,096 shares of the business’s stock in a transaction on Tuesday, August 16th. The shares were sold at an average price of $17.11, for a total transaction of $35,862.56. Following the completion of the transaction, the vice president now owns 1,996 shares in the company, valued at approximately $34,151.56. The disclosure for this sale can be found here.
IRADIMED CORPORATION (IRADIMED) develops, manufactures, markets and distributes Magnetic Resonance Imaging (MRI) compatible products, and provides non-magnetic intravenous (IV) infusion pump systems. The Company operates through development, manufacture and sale of MRI compatible products and IV infusion pump systems for use by hospitals and acute care facilities during MRI procedures segment.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.